Keppra Related Published Studies
Well-designed clinical trials related to Keppra (Levetiracetam)
Levetiracetam in the treatment of alcohol dependence: toward the end of the
story? [2012]
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam
extended-release in very heavy drinking alcohol-dependent patients. [2012]
Double-masked, placebo-controlled study of intravenous levetiracetam for the
treatment of status epilepticus and acute repetitive seizures in dogs. [2012]
The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. [2011.07]
Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. [2011.06]
Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid. [2011.06]
The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. [2011.05]
A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. [2011.05]
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. [2011.04]
Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). [2011.04]
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. [2011.02.01]
Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. [2011.02]
Spotlight on levetiracetam in epilepsy. [2011]
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's
disease. [2011]
A multicenter, randomized, placebo-controlled trial of levetiracetam in children
and adolescents with newly diagnosed absence epilepsy. [2011]
Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. [2010.12]
Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics. [2010.10]
Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. [2010.09]
Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. [2010.07]
Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. [2010.05]
Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. [2010.04]
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. [2010.04]
Assessment of behavioral and emotional functioning using standardized instruments
in children and adolescents with partial-onset seizures treated with adjunctive
levetiracetam in a randomized, placebo-controlled trial. [2010]
Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures
and Alzheimer's disease. [2010]
Levetiracetam in generalized social anxiety disorder: a double-blind, randomized
controlled trial. [2010]
Levetiracetam in spinal cord injury pain: a randomized controlled trial. [2009.12]
Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. [2009.11]
Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques. [2009.10]
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. [2009.07]
Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. [2009.07]
Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. [2009.06]
Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. [2009.06]
A prospective pilot study of levetiracetam for body dysmorphic disorder. [2009.05]
Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. [2009.05]
Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study. [2009.04]
Pharmacokinetics of levetiracetam XR 500mg tablets. [2009.04]
Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. [2009.03]
Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. [2009.03]
The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. [2009.03]
Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. [2009.03]
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. [2009.03]
Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures. [2009.01.29]
Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. [2009]
Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. [2009]
Bioequivalence of two formulations of levetiracetam. [2008.11]
Levetiracetam in absence epilepsy. [2008.11]
Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. [2008.09.12]
Effect of levetiracetam on the postmastectomy pain syndrome. [2008.08]
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. [2008.07.24]
Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. [2008.06]
Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. [2008.04]
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. [2008.02.19]
Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. [2008.02]
Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. [2008.02]
Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study. [2008.02]
The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. [2008]
Levetiracetam and bleeding disorders. [2007.12]
Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. [2007.11.27]
Levetiracetam is not effective for essential tremor. [2007.11]
Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. [2007.11]
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. [2007.10.30]
Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. [2007.10]
Impact of levetiracetam on mood and cognition during prednisone therapy. [2007.10]
A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. [2007.09.15]
Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. [2007.05]
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. [2007.02.06]
Influence of levetiracetame on ictal and postictal EEG in patients with partial seizures. [2006.12]
Assessment of a dose-response relationship of levetiracetam. [2006.09]
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. [2006.07]
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. [2006.06.13]
Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. [2006.05]
Specific effect of levetiracetam in experimental human pain models. [2006.04]
Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA). [2006.03]
Effects of levetiracetam on nocturnal sleep and daytime vigilance in healthy volunteers. [2006.01]
Efficacy and Safety of Levetiracetam (up to 2000 mg/day) in Taiwanese Patients with Refractory Partial Seizures: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. [2006.01]
Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. [2006]
Effects of levetiracetam on sleep in normal volunteers. [2005.11]
Levetiracetam in social phobia: a placebo controlled pilot study. [2005.09]
Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. [2005.05]
The effect of levetiracetam on essential tremor. [2005.03.22]
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. [2005.03]
Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. [2005.03]
Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function--a TMS study. [2004.11]
Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. [2004.11]
Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. [2004.10]
Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. [2003.12]
Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. [2003.05]
A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. [2003.04]
Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. [2003.02]
Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. [2003.02]
The effects of levetiracetam on objective and subjective sleep parameters in healthy volunteers and patients with partial epilepsy. [2002.09]
Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. [2002.07]
Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. [2002.05]
Levetiracetam: a different approach to the pharmacotherapy of epilepsy. [2002.02]
Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. [2002.01]
Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. [2001.11]
Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. [2001.08]
Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. [2000.12]
Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. [2000.10]
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. [2000.09]
Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. [2000.08]
|